Insider Buying: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Purchases 41,639 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of enGene stock in a transaction on Friday, September 27th. The shares were bought at an average price of $5.97 per share, with a total value of $248,584.83. Following the completion of the transaction, the insider now directly owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

enGene Stock Down 3.0 %

Shares of NASDAQ ENGN opened at $9.02 on Friday. The stock has a market cap of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene Holdings Inc. has a 12-month low of $4.42 and a 12-month high of $43.00. The company has a 50-day moving average of $6.71 and a 200 day moving average of $9.78.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. As a group, sell-side analysts predict that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and set a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $33.67.

Institutional Trading of enGene

Several large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in shares of enGene during the 1st quarter worth $17,095,000. SR One Capital Management LP purchased a new position in enGene during the second quarter worth about $4,715,000. Logos Global Management LP boosted its holdings in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. purchased a new stake in shares of enGene in the 1st quarter valued at approximately $2,039,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.